1-methyl-1-(2-phenylethyl)hydrazine | 14198-17-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-methyl-1-(2-phenylethyl)hydrazine
• 英文别名: N-methyl-N-phenethyl-hydrazine；N-methyl-N-phenethyl-hydrazine；N-Methyl-N-<β-phenyl-ethyl>-hydrazin；N-Methyl-N-phenethyl-hydrazin
• CAS: 14198-17-5
• 化学式: C₉H₁₄N₂
• 分子量: 150.224
• InChiKey: NYLHEAVZPYYUJZ-UHFFFAOYSA-N

物化性质

• 沸点：
  125 °C(Press: 17 Torr)
• 密度：
  1.003±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-methyl-1-(2-phenylethyl)hydrazine 在 palladium dihydroxide 草酰氯 、 acetate buffer 、 氢气 、 N,N-二甲基甲酰胺 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 1.75h， 生成
  参考文献：
  名称：

  A new type of ketolide bearing an N-aryl-alkyl acetamide moiety at the C-9 iminoether: Synthesis and structure–activity relationships (2)

  摘要：

  A new type of ketolide bearing an N-aryl-alkyl acetamide moiety at the C-9 iminoether and its analogues were prepared, and their antibacterial activities and pharmacokinetic properties were evaluated. We found that the introduction of all (R)-alkyl group between the amide and iminoether groups could improve the pharmacokinetic properties while maintaining the activity against erythromycin-resistant Streptococcus pneumoniae. Among the ketolides prepared with the (R)-alkyl group, compound 5p with an N-(3-quinoxalin-6-yl-propyl)-propionamide moiety was found to have in vivo efficacy comparable to CAM with potent in vitro antibacterial activities against the key respiratory pathogens including Haemophilus influenzae and erythromycin-resistant S. pneumoniae. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.01.036

文献信息

• [EN] THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS THÉRAPEUTIQUES DE PYRIDAZINE ET LEURS UTILISATIONS
  申请人：GENENTECH INC

  公开号：WO2016138114A1

  公开（公告）日：2016-09-01

  The present invention relates to compounds of formula (I): (I) and salts thereof, wherein: R1-R4 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of BRG1, BRM and/or PB1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various BRG1-mediated disorders, BRM-mediated disorders and/or PB1-mediated disorders.

  本发明涉及式(I)的化合物及其盐，其中：R1-R4具有规范中定义的任何值，以及其组合物和用途。这些化合物可用作BRG1、BRM和/或PB1的抑制剂。还包括包含式(I)的化合物或其药学上可接受的盐的药物组合物，以及在治疗各种BRG1介导的疾病、BRM介导的疾病和/或PB1介导的疾病中使用这些化合物和盐的方法。
• 2-chloro-N.sup.6 -substituted adenosines, their pharmaceutical
  申请人：Novo Nordisk A/S

  公开号：US05430027A1

  公开（公告）日：1995-07-04

  Adenosine compounds having the following structure ##STR1## wherein X is halogen, perhalomethyl, acetamido, cyano, C.sub.1-6 -alkoxy, C.sub.1-6 -alkylthio or C.sub.1-6 -alkylamino; and R.sup.1 is --NR.sup.2 R.sup.3 or YR.sup.4, wherein Y is oxygen or sulfur; R.sup.2 is phenyl, C.sub.1-6 -alkyl or substituted C.sub.1-6 -alkyl; and R.sup.4 is naphthyl, partly saturated naphthyl; optionally phenyl or phenoxy substituted C.sub.1-6 -alkyl wherein the phenyl and phenoxy substituents are also optionally substituted, or optionally phenyl or phenoxy substituted C.sub.3-8 -cycloalkyl and their pharmaceutically acceptable salts are useful in the treatment of myocardial and cerebral ischemias.

  具有以下结构的腺苷化合物：##STR1## 其中X是卤素，全卤代甲基，乙酰胺基，氰基，C.sub.1-6-烷氧基，C.sub.1-6-烷基硫基或C.sub.1-6-烷基氨基; R.sup.1是--NR.sup.2R.sup.3或YR.sup.4，其中Y是氧或硫; R.sup.2是苯基，C.sub.1-6-烷基或取代的C.sub.1-6-烷基; R.sup.4是萘基，部分饱和的萘基; 可选地为取代的C.sub.1-6-烷基，其中苯基和苯氧基取代基也可选地取代，或可选地为取代的C.sub.3-8-环烷基及其药学上可接受的盐，用于治疗心肌和脑缺血。
• Goetz,M.; Grozinger,K., Journal of Heterocyclic Chemistry, 1970, vol. 7, p. 123 - 129
  作者：Goetz,M.、Grozinger,K.

  DOI：——

  日期：——
• NOVEL ADENOSINE DERIVATIVES
  申请人：NOVO NORDISK A/S

  公开号：EP0607367A1

  公开（公告）日：1994-07-27
• US5430027A
  申请人：——

  公开号：US5430027A

  公开（公告）日：1995-07-04